Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Temozolomide for melanoma

Temozolomide (Temodal) is as effective as dacarbazine for metastatic melanoma and has the advantage of being an oral preparation, say Dr Mark Middleton (department of medical oncology, Christie hospital NHS trust, Manchester) and colleagues.

In a phase III trial involving 305 patients with advanced metastatic melanoma, temozolomide was compared with dacarbazine. Patients were given either oral temozolomide at a starting dose of 200mg/m2/day for five days every 28 days or dacarbazine 250mg/m2/day for five days every 21 days. The authors report that median survival was 7.7 and 6.4 months for temozolomide and dacarbazine, respectively, and median progression-free survival was 1.9 and 1.5 months. No major difference was seen in terms of toxicity. Dr Middleton says: “Temodal wins hands down over dacarbazine because it can be given to patients in capsule form, which they can take home instead of having to go to hospital for a very lengthy injection.”

Temozolomide is licensed in the UK for treatment of two types of brain tumour. It was developed by a team of pharmacists (PJ 1999;262:467). The new trial results are reported in the Journal of Clinical Oncology (2000;18:158).

Citation: The Pharmaceutical Journal URI: 20000212

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.